Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-25
DOI
10.1038/s41375-021-01277-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Outcome of T‐cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near‐ETP Phenotype & Differential Impact of Nelarabine
- (2021) Kiyomi Morita et al. AMERICAN JOURNAL OF HEMATOLOGY
- An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory P hiladelphia chromosome‐positive acute lymphoblastic leukemia
- (2021) Nicholas J. Short et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
- (2020) Liora M Schultz et al. BLOOD
- Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- (2020) Norman J. Lacayo et al. BLOOD
- Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- (2020) Nicholas J. Short et al. BLOOD
- Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
- (2020) Shuhong Shen et al. JAMA Oncology
- Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).
- (2020) Nitin Jain et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute lymphoblastic leukaemia
- (2020) Florent Malard et al. LANCET
- Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL
- (2020) Nicholas J. Short et al. Blood Cancer Journal
- Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
- (2020) Elias Jabbour et al. Lancet Haematology
- Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
- (2020) Kimberly P. Dunsmore et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
- (2020) Robin Foà et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
- (2019) Wendy Stock et al. BLOOD
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
- (2019) Juanjuan Zhao et al. Journal of Hematology & Oncology
- Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
- (2019) Amber C. King et al. LEUKEMIA RESEARCH
- Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
- (2019) Elias J. Jabbour et al. CANCER
- The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival
- (2019) Musa Yilmaz et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
- (2019) Persis J Amrolia et al. BLOOD
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
- (2018) Nicola Gökbuget et al. BLOOD
- Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia
- (2018) Elias Jabbour et al. Clinical Lymphoma Myeloma & Leukemia
- JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
- (2018) Sang-Kyu Kim et al. GENES & DEVELOPMENT
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
- (2018) Hagop Kantarjian et al. LANCET ONCOLOGY
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia
- (2018) Nicholas J. Short et al. Current Hematologic Malignancy Reports
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2018) Elias Jabbour et al. JAMA Oncology
- Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
- (2018) Wendy Stock et al. JOURNAL OF CLINICAL ONCOLOGY
- COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.
- (2018) Kimberly P. Dunsmore et al. JOURNAL OF CLINICAL ONCOLOGY
- Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
- (2018) Nicholas J. Short et al. AMERICAN JOURNAL OF HEMATOLOGY
- Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
- (2018) Sebastian Giebel et al. BONE MARROW TRANSPLANTATION
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
- (2018) Elias Jabbour et al. CANCER
- Early Response–Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study
- (2017) Jonathan Bond et al. JOURNAL OF CLINICAL ONCOLOGY
- High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults
- (2017) Kathryn G. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
- (2017) Giovanni Martinelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
- (2017) N Toft et al. LEUKEMIA
- Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
- (2017) J Duell et al. LEUKEMIA
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It
- (2017) Nicholas J. Short et al. Current Oncology Reports
- Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia
- (2017) Donald A. Berry et al. JAMA Oncology
- Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
- (2016) Nitin Jain et al. BLOOD
- Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2016) N. J. Short et al. BLOOD
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL
- (2016) Philippe Rousselot et al. BLOOD
- Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
- (2016) N. Jain et al. BLOOD
- Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
- (2016) Koji Sasaki et al. CANCER
- Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- (2016) Elias Jabbour et al. CANCER
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
- (2016) N. Gokbuget et al. HAEMATOLOGICA
- Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group
- (2016) Josep-Maria Ribera et al. LEUKEMIA RESEARCH
- Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
- (2016) Sébastien Maury et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
- (2016) Jessica T. Leonard et al. Science Translational Medicine
- International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
- (2016) N. Gokbuget et al. HAEMATOLOGICA
- Ph-like acute lymphoblastic leukemia
- (2016) T. H. Tran et al. Hematology-American Society of Hematology Education Program
- Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
- (2015) D.-Y. Kim et al. BLOOD
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients
- (2015) M. A. Pulsipher et al. BLOOD
- Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
- (2015) Y. Chalandon et al. BLOOD
- Monoclonal antibodies in acute lymphoblastic leukemia
- (2015) E. Jabbour et al. BLOOD
- Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
- (2015) N. Dhedin et al. BLOOD
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
- (2015) Farhad Ravandi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003
- (2015) Rachael Hough et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) Farhad Ravandi et al. CANCER
- BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
- (2015) S. E. Alford et al. CANCER RESEARCH
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
- (2015) Elias Jabbour et al. LANCET ONCOLOGY
- Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) N. Daver et al. HAEMATOLOGICA
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
- (2015) Kathryn G. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Chimerism and Minimal Residual Disease Monitoring for Relapse Prediction after Allogeneic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia
- (2014) Theis Helge Terwey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia
- (2014) K. Beldjord et al. BLOOD
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)
- (2014) Michael E. Rytting et al. CANCER
- Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
- (2014) Josep-Maria Ribera et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
- (2014) D J DeAngelo et al. LEUKEMIA
- Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group
- (2014) F Hayakawa et al. Blood Cancer Journal
- Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
- (2014) T. N. Chonghaile et al. Cancer Discovery
- Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations
- (2013) M. Neumann et al. BLOOD
- UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
- (2013) A. K. Fielding et al. BLOOD
- How I treat older patients with ALL
- (2013) N. Gokbuget BLOOD
- Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
- (2013) Hagop Kantarjian et al. CANCER
- Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study
- (2012) Aline Tanguy-Schmidt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- (2012) N. Gokbuget et al. BLOOD
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Anti-CD20 Antibody Therapy for B-Cell Lymphomas
- (2012) David G. Maloney NEW ENGLAND JOURNAL OF MEDICINE
- Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
- (2012) Huimin Geng et al. Cancer Discovery
- Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation
- (2011) Xiao-Su Zhao et al. ANNALS OF HEMATOLOGY
- High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation
- (2011) N. Gokbuget et al. BLOOD
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2011) R. Foa et al. BLOOD
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
- (2010) F. Ravandi et al. BLOOD
- A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study
- (2010) M. Hunault-Berger et al. HAEMATOLOGICA
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia
- (2010) Deborah A. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen
- (2009) John M. Storring et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993
- (2009) Bella Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
- (2009) Françoise Huguet et al. JOURNAL OF CLINICAL ONCOLOGY
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
- (2009) Elaine Coustan-Smith et al. LANCET ONCOLOGY
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
- (2009) Monique L Den Boer et al. LANCET ONCOLOGY
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia
- (2008) Susan O'Brien et al. CANCER
- Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96
- (2008) Josep-María Ribera et al. JOURNAL OF CLINICAL ONCOLOGY
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search